# US 7,611,705 B2 · Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,611,705 B2
- Document ID: US7611705B2
- Status: Granted
- Kind: B2
- Application number: 11/763,812
- Filed: 2007-06-15
- Published: 2008-12-18
- Granted: 2009-11-03
- Earliest claimed: 2007-06-15
- Assignees: National Cheng Kung University
- Inventors: Ming-Shi Chang
- Web page: https://patentgrep.com/patent/US7611705B2

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention features an antibody specifically binding to human IL-20 (e.g., mAb 7E and a equivalent thereof) and its use in treating an IL-20 associated inflammatory disease, such as atherosclerosis, RA, psoriasis, psoriatic arthritis, bacteria-induced gastric ulcer, and acute renal failure.

## Claims

### Claim 1

A method of treating an IL-20 associated inflammatory disease, the method comprising:
identifying a patient suffering from an IL-20 associated inflammatory disease, and administering to the patient an antibody, wherein the antibody contains a VH region including all of the complementarity-determining regions in the VH region of mAb 7E and a VL region including all of the complementarity-determining regions in the VL region of mAb 7E.

### Claim 2 (depends on 1)

The method of claim 1, wherein the IL-20 associated inflammatory disease is selected from the group consisting of RA, psoriasis, psoriatic arthritis, bacteria-induced gastric ulcer, and acute renal failure.

### Claim 3 (depends on 2)

The method of claim 2, wherein the IL-20 associated inflammatory disease is RA.

### Claim 4 (depends on 3)

The method of claim 3, wherein the antibody is administered directly to an arthritic joint.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody is mAb 7E.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibody is an antibody containing the VH and VL of mAb 7E.

### Claim 7 (depends on 6)

The method of claim 6, wherein the antibody is Fab, F(ab′)2, scFv, or chimeric antibody of mAb 7E.

### Claim 8 (depends on 1)

The method of claim 1, wherein the antibody is a humanized antibody of mAb 7E.